NCT03766854View on ClinicalTrials.gov

A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 7, 2018

Primary Completion Date

December 9, 2019

Study Completion Date

December 9, 2019

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

insulin icodec

Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks

DRUG

Insulin glargine U100

Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks

Trial Locations (1)

812-0025

Novo Nordisk Investigational Site, Fukuoka

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT03766854 - A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week | Biotech Hunter | Biotech Hunter